bullish

Biopharma Week in Review - October 21, 2024

176 Views23 Oct 2024 07:20
Issuer-paid
Last week, LBPH was acquired, providing a boost to comps PRAX, MRNS, JAZZ, and DRUG. Biopharma M&A may start seeing an uptick after a slow summer.
What is covered in the Full Insight:
  • Biopharma M&A Activities
  • RNA Editing and Regulatory Pathways
  • Clinical Updates: EXEL, JSPR, JAZZ, MGTX, AURA
  • Regulatory and Trial Setbacks: NVAX, GILD
  • Market Performance and Outlook
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Water Tower Research
Research from Water Tower Research
Water Tower Research
Equity Bottom-UpThematic (Sector/Industry)
  • Loading...
x